Health
AbbVie, Brise disclose deal for two preclinical migraine meds
AbbVie has agreed to a discovery and commercialization deal with Brise Pharma for two preclinical migraine programs. The Beijing-based partner said Monday the agreement actually stemmed from 2024. An investor relations ...
- Published
- (1 h ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 32-word snippet. The full article is at the source.
More from Endpoints News and around the same time
WuXi Biologics, Fresenius partner ahead of biosimilar boomWuXi Biologics and German drugmaker Fresenius have reached one of the largest biosimilar deals to date ahead of what some in the industry have called an upcoming “golden decade” for such products. ...UniQure gets review date and adcomm; Inovia's stock surges after approvalPlus news about AbbVie, Gilead and Tiziana Life Sciences. FDA gives uniQure a review date and adcomm: The agency will decide whether or not to approve UniQure’s high-profile Huntington’s disease gene therapy by May 1 ...Karyopharm plans to merge with Ayrmid, the company that tried buying bluebirdWith few options remaining, a commercial-stage blood cancer biotech will go through a bankruptcy process and plans to merge with another drugmaker in the blood disorder field. Karyopharm Therapeutics, maker of the multiple…FDA puts Bright Minds drug on partial hold, stock tanksThe FDA placed an experimental seizure drug from Bright Minds Biosciences on a partial clinical hold, the company announced Monday. Regulators issued the hold for BMB-101 after identifying toxicity issues in preclinical mouse…CinRx teams with Sam Waksal's Graviton on ROCK2 for PAH, other cardio conditionsSam Waksal is doubling down on ROCK2 after his first work on the target led to the chronic graft-versus-host disease medicine Rezurock. Now, the Graviton Bioscience CEO is teaming up with a cardio drug development ...Anthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and moreHello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but just noting that they’re actually made with bug secretions. The Atlantic has all ...This page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
